Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 23.9% – Should You Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) were up 23.9% on Monday . The stock traded as high as $10.76 and last traded at $10.53. Approximately 82,298,499 shares traded hands during mid-day trading, an increase of 344% from the average daily volume of 18,530,172 shares. The stock had previously closed at $8.50.

Analyst Ratings Changes

Several equities analysts have commented on RXRX shares. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. KeyCorp lowered their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th.

Recursion Pharmaceuticals Price Performance

The company has a 50 day moving average of $7.38 and a two-hundred day moving average of $6.95. The firm has a market cap of $4.25 billion, a P/E ratio of -7.10 and a beta of 0.86. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several large investors have recently made changes to their positions in RXRX. Allspring Global Investments Holdings LLC acquired a new stake in Recursion Pharmaceuticals during the third quarter valued at approximately $25,000. Decker Retirement Planning Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $26,000. Private Trust Co. NA bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth $27,000. GAMMA Investing LLC grew its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after acquiring an additional 4,948 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its position in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares during the period. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.